Anti-addiction drug ibogaine inhibits hERG channels: A cardiac arrhythmia risk

Addiction Biology

Volumn 19, Issue 2, 2014, Pages 237-239

  Koenig, Xaver ^a   Kovar, Michael ^a   Boehm, Stefan ^a   Sandtner, Walter ^a   Hilber, Karlheinz ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti addiction drug; cardiac arrhythmias; hERG potassium channels; ibogaine; indole alkaloid; QT interval prolongation

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; IBOGAINE; KCNH1 PROTEIN, HUMAN; POTASSIUM CHANNEL HERG;

ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; BEHAVIOR, ADDICTIVE; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HEART ARRHYTHMIA; HEART RATE; HUMAN; SECONDARY PREVENTION;

ADULT; ANIMALS; ARRHYTHMIAS, CARDIAC; BEHAVIOR, ADDICTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HEART RATE; HUMANS; IBOGAINE; SECONDARY PREVENTION;

EID: 84894491360     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2012.00447.x     Document Type: Article

References (9)

1. Alper KR, (2001) Ibogaine: a review. Alkaloids Chem Biol 56: 1-38.
2. Glick SD, Maisonneuve IS, (1998) Mechanisms of antiaddictive actions of ibogaine. Ann N Y Acad Sci 844: 214-226.
3. Hoelen DW, Spiering W, Valk GD, (2009) Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med 360: 308-309.
4. Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Hearn WL, Sanchez-Ramos J, (1998) Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci 844: 274-292.
5. Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, Singleton EG, Mayor M, (2000) Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci 914: 394-401.
6. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG, (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
7. Sanguinetti MC, Tristani-Firouzi M, (2006) hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
8. Vastag B, (2005) Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'. Science 308: 345-346.
9. Zebedin E, Koenig X, Radenkovic M, Pankevych H, Todt H, Freissmuth M, Hilber K, (2008) Effects of duramycin on cardiac voltage-gated ion channels. Naunyn Schmiedebergs Arch Pharmacol 377: 87-100.